Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS

Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s LGVN Lomecel-B. The drug candidate showed a 100% survival rate after 5 years in its ELPIS I trial, according to Longeveron.

The clinical stage biotechnology company develops cellular regenerative therapies that are patient focused and designed to combat a range of age-related diseases. It currently has several trials underway for diseases like HLHS, Alzeimer’s, and Aging Frailty.

Learn more here:

Featured photo by Louis Reed on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.